ConductScience.org, home

Paper40709686

Developing Biomaterial-Based mRNA Delivery System for Lung Disease Treatment.

Gu Q and 7 others. Adv Sci (Weinh), 2025. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Developing Biomaterial-Based mRNA Delivery System for Lung Disease Treatment. Papers, record 40709686. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40709686

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Developing Biomaterial-Based mRNA Delivery System for Lung Disease Treatment.
PubMed
Journal
Adv Sci (Weinh)
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
2.01, provisional
iCite
Revised in PubMed
2026-09-25
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gu QQiancheng
2Xue HHuaqian
3Liu ZZhiyun
4Rao JJiameng
5Zeng LLingyao
6Zhang CChen
7Lei LLanjie
8Shi LLiyunhttps://orcid.org/0009-0001-5853-2662

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Biocompatible MaterialsMajor topic
RNA, MessengerMajor topic
Lung DiseasesMajor topic
Drug Delivery SystemsMajor topic
Humans
Animals

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
822770014National Natural Scientific FundsPubMed
81991523National Natural Scientific FundsPubMed
2018YFC1705900National Key Research and Development Program ProjectPubMed
2024SZRYBH180001Natural Science Foundation of HangzhouPubMed

Source PubMed

Download CSV of grants

References194

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131690379Asthma in adults: Principles of treatment.Allergy Asthma Proc2019https://conductscience.org/library/papers/31690379PubMed
223743667Ciliated micropillars for the microfluidic-based isolation of nanoscale lipid vesicles.Lab Chip2013https://conductscience.org/library/papers/23743667PubMed
338040120Long-acting inhaled medicines: Present and future.Adv Drug Deliv Rev2024https://conductscience.org/library/papers/38040120PubMed
434504954Sodium-dependent phosphate transporter NaPi2b as a potential predictive marker for targeted therapy of ovarian cancer.Biochem Biophys Rep2021https://conductscience.org/library/papers/34504954PubMed
528150211Gene Silencing Using Multifunctionalized Gold Nanoparticles for Cancer Therapy.Methods Mol Biol2017https://conductscience.org/library/papers/28150211PubMed
628202367Exosomes: Therapy delivery tools and biomarkers of diseases.Pharmacol Ther2017https://conductscience.org/library/papers/28202367PubMed
738865465Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice.Sci Adv2024https://conductscience.org/library/papers/38865465PubMed
823111789Microfluidic filtration system to isolate extracellular vesicles from blood.Lab Chip2012https://conductscience.org/library/papers/23111789PubMed
935446546Surface Modification of Lipid-Based Nanoparticles.ACS Nano2022https://conductscience.org/library/papers/35446546PubMed
1032127636pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics.Commun Biol2020https://conductscience.org/library/papers/32127636PubMed
1139015802Robust anti-tumor immunity through the integration of targeted lipid nanoparticle-based mRNA nanovaccines with PD-1/PD-L1 blockade.Mater Today Bio2024https://conductscience.org/library/papers/39015802PubMed
1230368954Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I.Adv Mater2018https://conductscience.org/library/papers/30368954PubMed
1334699691The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.Cancer Commun (Lond)2021https://conductscience.org/library/papers/34699691PubMed
1431602823Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases.Wiley Interdiscip Rev Nanomed Nanobiotechnol2020https://conductscience.org/library/papers/31602823PubMed
1530390118The micromechanics of lung alveoli: structure and function of surfactant and tissue components.Histochem Cell Biol2018https://conductscience.org/library/papers/30390118PubMed
1632234467Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.Int J Antimicrob Agents2020https://conductscience.org/library/papers/32234467PubMed
1727710833CaCO3 nanoparticles as an ultra-sensitive tumor-pH-responsive nanoplatform enabling real-time drug release monitoring and cancer combination therapy.Biomaterials2016https://conductscience.org/library/papers/27710833PubMed
1839605063Targeting the tumor microenvironment with biomaterials for enhanced immunotherapeutic efficacy.J Nanobiotechnology2024https://conductscience.org/library/papers/39605063PubMed
1933400957Self-assembled mRNA vaccines.Adv Drug Deliv Rev2021https://conductscience.org/library/papers/33400957PubMed
2025260098Functional nanomaterials for phototherapies of cancer.Chem Rev2014https://conductscience.org/library/papers/25260098PubMed

See all 194 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42749398mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.J Genet Eng Biotechnol2026https://conductscience.org/library/papers/42749398PubMed
42733877Hyaluronic Acid-Modified Celecoxib-Loaded Nanostructured Lipid Carriers Combined with Dissolving Microneedles for Targeted Sustained-Release Therapy in Osteoarthritis.Int J Nanomedicine2026https://conductscience.org/library/papers/42733877PubMed
42493486Enhancing pulp regeneration through metabolic reprogramming of mature dental pulp stem cells mediated by GLUT1/HK2 mRNA delivery.Int J Oral Sci2026https://conductscience.org/library/papers/42493486PubMed
41728072Exosome Augmentation Technologies for Drug Delivery and Disease Treatment: A Review.Biomater Res2026https://conductscience.org/library/papers/41728072PubMed
40709686Developing Biomaterial-Based mRNA Delivery System for Lung Disease Treatment.Adv Sci (Weinh)2025https://conductscience.org/library/papers/40709686PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40709686

GET https://conductscience.org/api/papers/v1/40709686/references?page=2